Genome-wide association studies have identified more than 50 robust loci associated with systemic lupus erythematosus (SLE) susceptibility, and follow-up studies help reveal candidate causative genetic variants and their biological relevance contributing to the development of SLE. Epigenetic modulation is emerging as an important mechanism for understanding how the implicated genes interact with environmental factors. We review recent progress toward identifying causative variants of SLE-associated loci and epigenetic impact on lupus, especially genetic-epigenetic interactions that modulate expression levels of SLE susceptibility genes.
INTRODUCTION
The genome-wide association study (GWAS) approach, based on its ability to screen hundreds of thousands of single nucleotide polymorphisms (SNPs) across the genome in a hypothesis-free manner, has accelerated the discovery of genetic variations contributing to systemic lupus erythematosus (SLE). Eight GWAS in SLE (four in Europeanderived [1] [2] [3] [4] and four in Asian populations [5] [6] [7] [8] ) and subsequent meta-analysis and large-scale replication studies have identified a rapidly expanding number of risk loci exceeding the genome-wide significance level (P < 5 Â 10 -8 ) which are located within or near genes encoding products contributing to the pathogenesis of SLE. In some cases, follow-up fine mapping using increased dense markers, imputation and target resequencing help in localization of candidate causative variants that explain observed GWAS signals. Only few of such variants disrupt protein-coding sequences and most lie in noncoding regions of the genome. The emergence of genomic and epigenomic data sets, such as expression quantitative-trait loci (eQTL) and
Encyclopedia of DNA Elements (ENCODE) [9] , has revolutionized functional annotation of noncoding variants with potential impact on gene regulation through alterations in transcriptional activity, splicing, mRNA stability and epigenetic modifications. Here, we discuss non-human leukocyte antigen (HLA) SLE-associated loci grouped by biological pathways, highlighting those that have causative variants implicated with their functional roles experimentally investigated.
Environmental exposures of genetically predisposed individuals may modify SLE risk genes epigenetically, resulting in the development of SLE manifestations. Epigenetic processes refer to heritable modifications that regulate gene expression and alter cellular functions without changes in the genomic sequence. Commonly described epigenetic mechanisms include DNA methylation, histone modification and microRNAs (miRNAs). A recent study [10 && ] has revealed epigenomic elements enriched in the promoters of autoimmunity susceptibility genes, suggesting that epigenetic modifications may amplify genetic risks for autoimmune diseases. We summarize important findings in epigenetic changes and highlight geneticepigenetic interactions that operate in variants associated with SLE susceptibility.
SYSTEMIC LUPUS ERYTHEMATOSUS SUSCEPTIBILITY GENES STRATIFIED BY BIOLOGICAL PATHWAYS
Non-HLA SLE-associated genes are summarized in [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] . We discuss genes that have the most likely causative variants implicated and functional consequences relevant to the disease pathogenesis.
Type I interferon pathway
Integration of data from GWAS, gene expression microarrays and serologic studies support that dysregulation of type I interferon (IFN) serves as a central driver of SLE pathogenesis [55] . The diverse mechanisms by elevated type I IFN affecting SLE development include promoting differentiation of monocytes and plasmacytoid dendritic cells, activation of autoreactive B and T cells, production of autoantibodies and expression of proinflammatory cytokines and chemokines [56] . Over half of the currently identified SLE susceptibility genes encode proteins that can be directly or indirectly linked to type I IFN production or signaling [55] .
Binding of immune complexes containing selfantigens and nucleic acids by pattern recognition receptors, such as TLR7, is a likely major trigger of type I IFN production in SLE. The importance of TLR7 upregulation in mediating autoimmune responses has been clearly demonstrated in murine lupus models [57] [58] [59] . Our group has identified a functional SNP at 3 0 untranslated region (UTR), exhibiting consistent association with SLE in four major ancestries [25,26 && ]. This SNP maps within a binding site for miRNA-3148 conferring allelic modulation of TLR7 expression. The SLE-risk allele confers decreased degradation of TLR7 transcripts, resulting in elevated TLR7 levels and heightened downstream IFN response [26 && ]. IRF5, IRF7 and IRF8, a family of transcription factors downstream of endosomal TLRs, are required for activating transcription of IFN-a and IFN-inducible genes. Genetic variants in or near these three genes have been associated with SLE susceptibility [3, [16] [17] [18] [19] [20] 22, 24] . In particular, SLE-associated variants of IRF5 and IRF7 have a functional impact on increased serum IFN-a, and such an impact depends on the presence of specific autoantibodies [21, 60] . A cis-eQTL SNP located within the SLEassociated haplotype not only is associated with IRF7 expression but also confers the trans-eQTL effect on regulating type I IFN response in activated but not unstimulated dendritic cells [61 && ], highlighting the importance of using appropriate activated ex-vivo cells to explore functional roles of the disease-associated variants.
Other genes related to the type I IFN pathway that are associated with increased risk for SLE include IFIH1 [11 && ], STAT4 [3, 5, 13, 14] , TYK2 [12] and SLC15A4 [5, 20, 23] . IFIH1, a cytosolic sensor of dsRNA, promotes IRF7 or 3 phosphorylation and type I IFN production. Three independent variants at IFIH1 (one intronic and two missense SNPs) account for genetic association in multiple ancestries [11
&&
]. Risk alleles of both missense variants confer increased apoptosis and elevated expression of inflammation-related genes. The intronic risk allele leads to decreased IFIH1 transcript levels by disruption of binding to protein complex including nucleolin and lupus autoantigen Ku70 or 80, which would be expected to promote autoantibody generation.
Nuclear factor kB pathway
Genes that function in the nuclear factor kB (NFkB) pathway downstream of TLR engagement have been associated with increased SLE risk in multiple KEY POINTS Over 50 loci associated with SLE susceptibility have been identified across multiple ancestries, and most encode gene products participating in the key pathways relevant to SLE pathogenesis.
Few of candidate causative variants are located in the coding sequences to affect protein functions, whereas many reside within noncoding regions to regulate gene expression through transcriptional and posttranscriptional mechanisms.
Epigenetic changes, such as DNA methylation, histone modification and miRNA regulation in SLE, represent an important layer to link genetics and gene expression with disease risk.
Integration of genetic knowledge into diverse biological studies promises to identify specific immune cells and important (or novel) pathways that present therapeutic targets for SLE drug development. ]. Functional consequences of the MECP2 risk haplotype will be discussed in the DNA methylation section.
B and T cell signaling
Multiple loci that mediate signaling transduction in B and T cells are associated with SLE, supporting a central role of dysregulated lymphocytes in the pathogenesis of SLE.
The R620W SNP of PTPN22 is a well characterized functional variant associated with multiple autoimmune diseases including SLE. Both humans carrying the risk 620W allele and knockin mice expressing the analogous 619W mutation show altered T-cell receptor (TCR) and B-cell receptor (BCR) signaling as well as enhanced B cell autoreactivity, illustrating the consequences of the risk variant in modulating T and B cell tolerance and autoimmunity [30] [31] [32] [33] [34] . Efforts to elucidate the role of R620W in nonlymphocytes have revealed that the risk 620W allele is associated with reduced TRAF3 (TNF receptor-associated factor 3) autopolyubiquitination and diminished TLR-induced type I IFN production in myeloid cells [64] , but with enhanced functions in neutrophils including increased transendothelial migration, Ca 2þ release and reactive oxygen species (ROS) production [65 & ]. Taken together, this PTPN22 polymorphism affects multiple signaling pathways in diverse immune cell types contributing to autoimmunity.
CSK encoding c-Src tyrosine kinase can regulate activation of Src kinases (e.g. LYN) by physical interaction with LYP (encoded by PTPN22) in lymphocytes. Association of CSK with SLE identified in European population has been localized to an intronic SNP as causal [44] . The SLE-risk allele is associated with high CSK expression, increased phosphorylation of Lyn, enhanced BCR-mediated activation of mature B cells and expansion of transitional B cells, suggesting CSK involvement in multiple development stages of B cells [44] . Integrating gene-expression data with SLE-associated loci has implicated transitional B cells to be appropriate for investigating functional consequences of risk alleles [66] , such as CSK. BANK1, encoding an adaptor protein, facilitates the release of intracellular calcium and alters the B cell activation threshold [2] . Three functional BANK1 variants, including one intronic and two missense SNPs, have been associated with SLE in multiple ancestries, which contributes to sustained BCR signaling and B cell hyperactivity characteristic of SLE [2] . BLK encodes a member of the Src family kinases functioning in intracellular signaling and the regulation of B cell proliferation, differentiation and tolerance [1] . Risk alleles of the BLK promoter variants account for genetic associations in multiethnic populations, and reduce promoter activity in B cell lines representing different B cell developmental stages, which suggests that decreased BLK expression may affect B cell development and impair functional responses in B cells [41 && ]. Interleukin-10 is a pivotal cytokine that inhibits T cells and antigen-presenting cells, while enhancing B cell survival and activity [67] . Our group has identified an IL10 upstream SNP that tags a risk haplotype associated with SLE in a European population [36 && ]. The SLE-risk allele is associated with increased IL10 expression by preferentially binding to the phosphorylated transcription factor Elk-1. Interestingly, SLE patients with active disease show enhanced phosphorylated Elk-1 in nuclei and elevated coexpression of interleukin-10 and phosphorylated Elk-1 in peripheral lymphocytes, suggesting the involvement of aberrant Elk-1 activation in development of SLE.
IKZF1 regulates lymphocyte differentiation, proliferation and BCR signaling [68] . The first evidence supporting IKZF1 as SLE susceptibility gene comes from a Chinese GWAS [5] . Recently, a trans-eQTL study [40 && ] has revealed the SLE-associated SNP at upstream of IKZF1 that alters the IKZF1 levels in cis and regulates expression of C1QB and five type I IFN response genes in trans, thereby reinforcing the importance of IKZF1 in SLE. This study illustrates how trans-eQTL mapping helps yield insights into downstream effects of the disease-associated variants.
Other genes with roles in B and T cell functions associated with SLE susceptibility are summarized in Table 1 , and most of them await delineation of functional mechanisms by which the associated variants affect disease risks.
Immune complex clearance
Defective clearance of immune complexes and apoptotic cells leads to initiation and maintenance of autoimmune responses and chronic inflammation in SLE. Polymorphisms in multiple members of this pathway have been associated with SLE, for example, missense variants of FCGR2A, FCGR3A and ITGAM and decreased copy number variations of FCGR3B (reviewed in [47] ). CD11b encoded by ITGAM together with CD18 form the complement receptor 3 with functions in binding to tissue-deposited immune complexes as well as leukocyte phagocytosis, apoptosis, adhesion and migration via interaction with a range of ligands, such as ICAM1 that has also shown association with SLE susceptibility [46] . The SLE-risk allele of ITGAM that encodes an amino acid change from Arg to His at position 77 (R77H) in CD11b impairs the complement receptor 3-mediated phagocytosis in monocytes, neutrophils and macrophages [48] [49] [50] . Given its location within an active chromatin region in ITGAM, the SLE-risk 77H allele confers reduced transcriptional enhancer activity and is associated with decreased ITGAM expression at both mRNA and protein levels in monocytes [69] .
Nicotinamide adenine dinucleotide phosphate oxidase-dependent reactive oxygen species pathway ROS produced by nicotinamide adenine dinucleotide phosphate (NADPH) oxidase complex are essential in defense against invading pathogens and are likely to promote cellular and tissue damage owing to their highly reactive nature [70] . Considering the proinflammatory effect, ROS have been implicated in promoting autoimmune diseases, such as SLE, rheumatoid arthritis (RA), thyroiditis and type 1 diabetes [71 & ,72-74] . A surprising finding of a polymorphism in the rat Ncf1 gene (encoding a subunit of NADPH oxidase complex) leading to low NADPH oxidase activity and reduced ROS production associated with severe arthritis in rodents provides a new insight into an anti-inflammatory role for ROS involved in autoimmune diseases [75, 76] . In fact, increasing evidence supports that ROS are not only proinflammatory byproducts of cellular responses to infectious or inflammatory stimuli but also act as fine-tuning regulators of autoimmune responses varying in time, location and extent of the ROS production (reviewed in [77] ). Consistently, a mutation (H389Q) in human NCF2 gene (encoding another subunit of NADPH oxidase complex) has been identified to associate with SLE risk in a European population, which is also accompanied by decreased NADPH oxidase activity and ROS production [51] . A large-scale transancestral replication study [52] has confirmed this mutation with SLE susceptibility in African American and Hispanic populations but not in Koreans (because of the absence of minor allele), and identified additional independently associated variants at NCF2 in all of the three non-European populations.
Other loci
Other pathways implicated by genetic findings have potential relevance to the SLE pathogenesis, including cell-cycle regulation (CDKN1B), autophagy (ATG5 and DRAM1) and DNA demethylation (TET3); however, further functional characterization is required [38 & ]. In addition, SLE-associated loci (e.g. TMEM39A, UHRF1BP1 and CLEC16A) with unknown immune function require further fine mapping and characterization of functional pathways contributing to the development of SLE [24, 53, 54] .
CONNECTING GENOTYPE TO PHENOTYPE IN SYSTEMIC LUPUS ERYTHEMATOSUS
Recent genotype-phenotype association studies provide insights into genetic effects on clinical subphenotypes. Multiple established SLE-risk loci are associated with anti-dsDNA autoantibody (e.g. HLA-DR2/DR3, STAT4, IRF5/IRF7, IFIH1, ITGAM and UBE2L3) [78] and/or renal disorders (e.g. ITGAM, STAT4, TNFSF4, TNFAIP3 and TNIP1) [79, 80] . In addition, the apolipoprotein L1 nephropathy risk alleles G1 and G2 strongly impact the risk and the time of end-stage renal disease (ESRD) in African Americans with lupus nephritis, which may partly explain the increased risk of lupus nephritis-ESRD in African Americans due to the high frequency of these alleles in African Americans but near absence in European Americans [81] . An analysis of specific manifestations with 22 validated SLE susceptibility loci has shown cumulative genetic associations with age at diagnosis, anti-dsDNA autoantibody, oral ulcers, immunological and hematologic disorders, single marker association with renal disorders and arthritis, and no genetic association with malar or discord rash, photosensitivity, serositis and neurological disorder [82] . Such measures will be improved as more new SLE-risk loci are emerging, which help enhance the link between genotype and phenotype in SLE.
EPIGENETICS IN SYSTEMIC LUPUS ERYTHEMATOSUS
The disease concordance rate of SLE in monozygotic twins (24-58%) suggests epigenetic contribution to the disease development. Dysregulated epigenetic modifications, including DNA methylation, histone modification and noncoding RNA, can affect the expression and function of genes participating in pathogenic processes of SLE.
DNA hypomethylation
DNA methylation usually occurs at the 5 0 position of cytosine in the context of CpG dinucleotides distributed in genomes exhibiting suppressive effects on gene expression. A role of DNA hypomethylation in SLE has been demonstrated in studies showing demethylating drug-induced T cell autoreactivity and lupus-like symptoms in mice and impaired DNA methylation in CD4 þ T cells from active SLE patients (reviewed in [83] ). Many methylationsensitive genes are overexpressed in SLE CD4 þ T cells, functionally contributing to SLE development, including CD11A causing autoreactivity, perforin increasing apoptosis, CD70 and CD40L enhancing B-T cell interaction for autoantibody production (reviewed in [84] ). Genome-wide DNA methylation analysis has shown severe hypomethylation of type I IFN-regulated genes in SLE CD4 þ T cells, CD19 þ B cells and CD14 þ monocytes, suggesting epigenetically mediated type I IFN hyper-responsiveness in SLE patients [85 && ,86] . Interestingly, healthy individuals carrying the SLE-risk IRAK1-MECP2 haplotype (mentioned in the NFkB pathway section) with increased levels of a specific MECP2 transcript isoform in stimulated T cells showed a similar hypomethylation of IFN-regulated genes, providing evidence for genetic-epigenetic interaction associated with SLE-risk variants [29 && ]. How DNA hypomethylation occurs in SLE patients is discussed in a recent review [87 many active genes, but H3 trimethyl-lysine9 or trimethyl-lysine27 in repressed genes [89] . Changes in histone modifications have been reported in SLE cells, leading to aberrant gene expressions that may contribute to SLE pathogenesis. For example, monocytes from SLE patients are characterized by global H4 hyperacetylation in parallel with increased expression of genes involved in type I IFN and NFkB pathways [90] . By integrating genetic and epigenetic data sets, active histone marks are enriched in the promoters of SLE and RA susceptibility genes in Epstein-Barr virus-transformed lymphoblastoid cell lines, suggesting a regulatory role of epigenomic elements for functions and cellular specificity of these autoimmune-associated genes [ 
MicroRNA dysregulation
MiRNAs representing a large class of small noncoding RNAs regulate gene expression by targeting specific mRNAs for degradation or translation inhibition [92] . Increasing evidence supports miRNAs playing an essential role in the development, homeostasis and function of innate and adaptive immunity that dysregulation of these processes may induce autoimmunity and inflammation (reviewed in [93] ). Studies of miRNA expression profiles in blood cells, plasma and target tissues from SLE patients have revealed unique miRNA signatures when compared with healthy individuals and dysregulation of miRNAs associated with disease activity and major organ involvement, suggesting miRNAs as biomarkers for SLE patients [ [96] ; second, exacerbation of inflammatory responses by increasing cyto or chemokine secretion (e.g. miR-125a, miR-23b) [97, 98] ; and third, reduction of DNA methylation by directly or indirectly inhibiting DNA methyltransferase 1 (e.g. miR-126, miR-148a, miR-21) [101, 102] . Of interest, the SLE-risk allele of miR146a promoter variant confers lower levels of its transcript because of decreased binding of transcription factor Ets-1 [15] . Given the great potential for variation in miRNA target sites, some SLE-associated SNPs located in 3 0 UTR could regulate gene expression through introducing or abolishing miRNA binding sites (e.g. TLR7) [26 && ], providing a miRNA-based genetic-epigenetic interaction for dissecting functional consequences of SLE-associated variants.
CONCLUSION
GWAS and follow-up studies have rapidly advanced our understanding of SLE genetics. Future challenges include discovery of new associations responsible for the missing heritability of SLE and identification of causal variants with functional characterization at each locus. It is likely that genetic variants may not explain all variations in gene functions contributing to SLE. Identifying epigenetic modulation and genetic-epigenetic interaction will unravel new mechanisms to understand how SLE susceptibility genes affect disease risk and phenotypic expression. Integration of genetic knowledge with diverse epigenomic and biological studies has already guided drug discovery for RA [103 && ], and such a systematic strategy will be applied to SLE in the near future. 
